



**Summit Therapeutics plc**  
(‘Summit’ or the ‘Company’)

**Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019**

**Oxford, UK, and Cambridge, MA, US, 24 September 2019** – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with *C. difficile* infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC. These data further strengthen the connection of ridinilazole’s microbiome preservation to its superior clinical outcomes over the standard of care, vancomycin, in a Phase 2 clinical trial as well as provide insight into the beneficial effect of ridinilazole treatment on the physical and mental effects of CDI in the trial. Details of the poster presentations are below.

**Date:** Thursday, 3 October 2019

**Time:** 12:15-1:30pm EDT

**Title:** Quality of Life Changes in Patients with *Clostridium difficile* Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)

**Session:** 068. Novel Antimicrobials and Approaches Against Resistant Bugs

**Authors:** S. Paul, R. Vickers and K. Garey

**Date:** Saturday, 5 October 2019

**Time:** 12:15-1:30pm EDT

**Title:** Narrow-spectrum Antibiotic Treatment of *Clostridium difficile* Infection Improves Preservation of Intestinal Metabolic Profile

**Session:** 267. Microbiome, Antibiotics and Pathogenesis

**Authors:** S. Park, K. Yanagi, A. Kane, D. Snyderman, R. Vickers, C. Thorpe and K. Lee

**Date:** Saturday, 5 October 2019

**Time:** 12:15-1:30pm EDT

**Title:** Effect of Broad vs. Narrow Spectrum *Clostridioides difficile* Treatment on Human Stool Bile Acid Composition Over Time

**Session:** 267. Microbiome, Antibiotics and Pathogenesis

**Authors:** C. Thorpe, X. Qian, K. Yanagi, A. Kane, N. Alden, D. Snyderman and K. Lee

Copies of the presentations will be available at the start of the poster sessions in the Publications section of Summit’s website, [www.summitplc.com](http://www.summitplc.com).

**About Summit Therapeutics**

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by *C. difficile*, *N. gonorrhoeae* and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit [www.summitplc.com](http://www.summitplc.com) and follow us on Twitter @summitplc.

**Contacts**

**Summit**

Glyn Edwards / Richard Pye (UK office)

Michelle Avery (US office)

**Tel:** 44 (0)1235 443 951

+1 617 225 4455



**Cairn Financial Advisers LLP** (Nominated Adviser)  
Liam Murray / Tony Rawlinson

**Tel:** +44 (0)20 7213 0880

**N+1 Singer** (Joint Broker)  
Aubrey Powell / Jen Boorer, Corporate Finance  
Tom Salvesen, Corporate Broking

**Tel:** +44 (0)20 7496 3000

**Bryan Garnier & Co Limited** (Joint Broker)  
Phil Walker / Dominic Wilson

**Tel:** +44 (0)20 7332 2500

**MSL Group (US)**  
Erin Anthoine

**Tel:** +1 781 684 6652  
[summit@mslgroup.com](mailto:summit@mslgroup.com)

**Consilium Strategic Communications (UK)**  
Mary-Jane Elliott / Sue Stuart / Sukaina Virji  
Lindsey Neville

**Tel:** +44 (0)20 3709 5700  
[summit@consilium-comms.com](mailto:summit@consilium-comms.com)

-END-